Saturday 17 October 2026
Export IMMP’s income statement to Excel — free account
Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
3.20
0.01
−0.31%
Follow IMMP
Prima BioMed Ltd (IMMP) P/E ratio
Prima BioMed Ltd has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (April 2021) to 0.0× (April 2021) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2017 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MCRB Seres Therapeutics, Inc. compare | n/m |
| ABVC ABVC BioPharma, Inc. compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | n/m |
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| BYSI BeyondSpring Inc. compare | n/m |
| IMMP Prima BioMed Ltd | n/m |
| CYAD Celyad SA compare | n/m |
| PLRZ Polyrizon Ltd. compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)